The positive proof-of-concept data from Cohort 1, combined with FDA alignment on a pivotal endpoint and a large addressable patient population, significantly de-risks the OPGx-BEST1 program. Traders should watch for Cohort 2 data in Q2 2027 and pivotal trial initiation in 2027 as key catalysts. The immaterial correction in this 8-K does not change the program's trajectory.
Price Chart
Executive Summary
Opus Genetics filed an 8-K correcting an immaterial error in the translation of logMAR visual acuity into ETDRS letters on a slide from its September 9 investor presentation. The core clinical data from the OPGx-BEST1 Phase 1/2 Cohort 1 remains unchanged: the therapy was well-tolerated with no SAEs or DLTs, 75% of evaluable participants met the FDA-aligned microperimetry endpoint, and the company has FDA alignment on a potential pivotal endpoint. The correction does not alter the program's fundamental outlook.
Key Facts
- OPGx-BEST1 was well-tolerated in 5/5 participants with no SAEs, DLTs, or intraocular inflammation.
- 75% (3/4) of evaluable participants met the FDA-aligned microperimetry threshold of 3 dB improvement in 5 prespecified loci.
- FDA Type C meeting aligned on potential pivotal endpoint using microperimetry anchored to a patient-reported outcome.
- Cohort 2 (high dose) is over-enrolled at 8 participants; dosing expected to complete Q4 2026, with 3-month data expected Q2 2027.
- New epidemiology estimates 23,600 BEST1 symptomatic patients in the U.S.
- Current cash runway extends into 2029, funding five clinical programs through multiple inflection points.
- The 8-K corrects an immaterial error in BCVA translation on Slide 15; individual corrected letter changes are provided for each participant.
Financial Impact
No financial figures reported; pre-revenue clinical-stage biotech with cash runway into 2029.
Risk Factors
- Clinical data is from a small, open-label Phase 1/2 study (n=5) and may not replicate in larger trials.
- Cohort 2 data and pivotal trial results are still 6-12 months away, creating execution risk.
- Gene therapy manufacturing and regulatory approval remain complex and uncertain.
- Company is pre-revenue and will require additional capital beyond current runway to fully commercialize.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-036277 |
| Document: ef20081922_8k.htm | 0001140361-26-036277 |
| Document: 0001140361-26-036277-index-headers.html | 0001140361-26-036277 |
| Document: 0001140361-26-036277-index.html | 0001140361-26-036277 |
| Document: 0001140361-26-036277.txt | 0001140361-26-036277 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 144 | $3.52 | awaiting T+60 | — | $3.32 (−5.68%) |
Oct 21, 2026 5d ago | 8-K | $3.82 | awaiting T+60 | — | $3.32 (−13.09%) |
Oct 15, 2026 11d ago | 8-K | $3.84 | awaiting T+60 | — | $3.32 (−13.54%) |
Oct 15, 2026 11d ago | Press Release | $3.84 | awaiting T+60 | — | $3.32 (−13.54%) |
Sep 22, 2026 4w ago | Institutional Cluster | $5.16 | awaiting T+60 | — | $3.32 (−35.66%) |
Sep 11, 2026 6w ago | 8-K | $6.04 | awaiting T+60 | — | $3.32 (−45.03%) |
Sep 9, 2026 6w ago | 8-K | $5.73 | awaiting T+60 | — | $3.32 (−42.06%) |
Sep 2, 2026 7w ago | Press Release | $4.45 | awaiting T+60 | — | $3.32 (−25.39%) |
Aug 6, 2026 11w ago | 8-K | $3.72 | awaiting T+60 | — | $3.32 (−10.75%) |
Jul 23, 2026 13w ago | 144 | $2.92 $4.05 | ▲ +38.70% | ▲ +34.15% | $3.32 (+13.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers